The FDA approval of Vimkunya has given the chikungunya vaccine’s owner, Bavarian Nordic, an extra financial windfall. | The ...

A landmark global modeling study reveals that more than 2.8 billion people in 104 countries are at risk of chikungunya, with ...

Valneva has reported encouraging six-month safety and antibody persistence data from the multi-centre Phase II trial, VLA1553 ...

Local door-to-door surveys will be conducted to check for symptoms in other residents of the commune, and thorough scans of ...

UK's medicine regulator said on Monday it has temporarily restricted the use of French vaccine maker Valneva's shot to treat ...

Dr. Harindu Wijesinghe is a medical specialist in Rheumatology and Rehabilitation, as well as in Sports Medicine. He ...

As the country grapples with rising cases of coronavirus and mosquito-borne dengue, there has been a resurgence of another mosquito-borne disease, Chikungunya, in Dhaka.

Results from the Phase II VLA1553-221 trial show that a full dose of Ixchiq demonstrated a 96.5% seroresponse rate in ...

Climate change is reshaping Europe’s disease landscape, with tropical mosquito-borne illnesses like dengue and chikungunya ...

Hundreds of cases have been imported in recent months after an outbreak in Réunion. The disease is spread by tiger mosquitoes ...

The UK’s Medicines and Healthcare products Regulatory Agency said that following global reports of serious adverse events in ...